In 479 analysed patients with relapsed or refractory multiple myeloma exposed to anti-CD38 antibodies and lenalidomide, adding mezigdomide to carfilzomib-dexamethasone improved median PFS (18·0 vs 8·3 months; HR 0·48), with more grade 3–4 adverse events (84% vs 56%).
RCTn = 479
Dimopoulos et al. Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial